|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||24.53|
|Dividend & Yield||1.03 (3.00%)|
|1y Target Est||N/A|
In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.
We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.
Bioverativ stock popped Wednesday after the Biogen spinoff announced a $400 million acquisition of True North Therapeutics.